When I think of the promise of stem cells for diabetes, the privately held California stem cell firm ViaCyte is the first biotech that comes to mind now. It has promising stem cell clinical trial work building. Today’s post is a new interview with the company’s CEO Paul Laikind. For past posts on ViaCyte see here, which …
ViaCyte Interview on Diabetes Stem Cell Trials & Cool Role of Gore-Tex Tech Read More »
There has been considerable discussion about the whether the media hyped the recent Harvard stem cells for diabetes paper (see top 10 takeaways of that paper). I believe that this was greatly hyped. This Harvard publication reported production of insulin-secreting cells from human embryonic stem cells (hESC). Newspapers around the world widely exaggerated the potential impact …
Stem cells for Diabetes: the danger of the word ‘cure’ Read More »
The idea of using stem cells for treat Type I Diabetes is very promising and could have huge practical impact. Real progress has been achieved toward this goal over the last decade. In perhaps another decade there might be a validated treatment. A new stem cell paper has just come out in Cell from Harvard in this …
Takeaways From Harvard Stem Cells for Diabetes Paper Read More »
I finally got a chance to read the Cell paper by the Melton team on Betatrophin and it is quite cool. Update — Unfortunately the Betatrophin paper discussed here originally back in 2013 has now largely been proven to have come to incorrect conclusions (for more read this). I think one big question is whether …
More on Betatrophin, my take on the Cell paper, and a video Read More »